Targeting the Dimerization of the Main Protease of Coronaviruses: A Potential Broad-Spectrum Therapeutic Strategy

Area of Science:

• Virology
• Biochemistry
• Drug Discovery

Background:

• Severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) causes the COVID-19 pandemic.
• SARS-CoV-2 shares significant genomic similarity with SARS-CoV.
• The main protease (Mpro), also known as 3CLpro, is essential for coronavirus replication and a promising therapeutic target.

Purpose of the Study:

• To review the impact of mutations and N-terminal deletions on SARS-CoV Mpro dimerization and catalytic activity.
• To highlight the potential of peptide-based inhibitors targeting Mpro dimerization for antiviral drug development.
• To emphasize the urgent need for novel antiviral agents against current and future coronavirus outbreaks.

Main Methods:

• Literature review of studies on SARS-CoV Mpro mutations and N-terminal deletions.
• Analysis of the relationship between Mpro structural modifications, dimerization, and enzymatic function.
• Compilation of data on the conserved nature of Mpro across coronaviruses.

Main Results:

• Mpro is highly conserved among coronaviruses, making it a stable drug target.
• Mutations in Mpro can be lethal to the virus, suggesting its critical role.
• Targeting Mpro dimerization with inhibitors offers a strategy to reduce drug resistance and achieve broad-spectrum activity.

Conclusions:

• Understanding Mpro's structural dynamics is key to designing effective antiviral therapies.
• Peptide-based inhibitors targeting Mpro dimerization show therapeutic promise.
• Continued research is vital for developing countermeasures against coronaviruses.